
Protagenic Therapeutics proposes up to US$5M placement for anxiety trial
Only US$1.5 million is upfront; the balance depends on warrants, with first U.S. patient dosing targeted for the second quarter of 2027.

Only US$1.5 million is upfront; the balance depends on warrants, with first U.S. patient dosing targeted for the second quarter of 2027.

Participation notices and a subscription agreement would preserve three investors' stakes, with closing expected Nov. 6.

A special-purpose subsidiary will issue the bonds, while Freedom guarantees obligations and project funding requires staged approvals.
Receipt conversion would give Goldgroup a 19.9 per cent stake after the Cozamin acquisition, with board nomination rights tied to ownership.
New shares would represent 15.6 per cent of enlarged capital, with one two-year warrant attached to each placing share.
Cash is payable at closing, subject to antitrust conditions; two announced voucher agreements total US$413 million.
Orexo expects to announce final issue terms preliminarily on Nov. 3 and plans a shareholder vote for Nov. 6.
Seraxis notes are expected to convert into BetaNova stock if the merger closes; the first SR-02 patient dose is targeted for Q1 2027.
A signed trial pact covers ivonescimab and sonesitatug vedotin in gastrointestinal cancers; Summit expects the share sale to close by Oct. 2.
Free online resource designated as 'The Green Pages' intended to serve cannabis industry through streamlined list of banking options
Company revenue increased 49% year over year and 1% sequentially, but annual operational costs increased by 111%
The company sought protection as a result of declining revenue stemming from COVID-19 government mandates
Humble & Fume invested US$8 million into the joint venture, with Green Acre Capital Distribution Corp. making a US$2 million investment
The firm says the low interest rate will allow it to refinance its debt
Narbé Alexandrian speaks on his firm's approach to deal-making, why software has become more attractive and the future consolidation of cannabis retail
With Premier Horgan's stated goal of restoring 'legendary' status to provincial product, there should be more money where his mouth is
Research, therapeutic and medical drug development and investment can all flourish under pre-existing legal pathways, experts say
Businesses have to apply through a bank, many of which still refuse to work with cannabis
Analysis: Business professor says weed companies have to make tough decisions to survive the oncoming recession, as his did in the dot-com era
Massive bonuses and mansions drew the ire of shareholders in MedMen, which demoted its CEO on Friday
Developed brands and cash flow will separate the winners from the losers over the next 12 months
The Quebec-based producer diluted the value of its existing stock by issuing more shares as it also reported a $2.4 million write-down on 'cannabis trim'
The company says it will use the proceeds to finish building its Ancaster, Ont., processing facility
Interim CEO says his company has the largest non-diluted cash balance in the cannabis industry